121 related articles for article (PubMed ID: 31929384)
1. Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case.
Whiteway SL; Betts AM; O'Neil ER; Green AL; Gilani A; Orr BA; Mathis DA
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e813-e818. PubMed ID: 31929384
[TBL] [Abstract][Full Text] [Related]
2. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
[TBL] [Abstract][Full Text] [Related]
3. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
4. Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3).
Coccé MC; Mardin BR; Bens S; Stütz AM; Lubieniecki F; Vater I; Korbel JO; Siebert R; Alonso CN; Gallego MS
Genes Chromosomes Cancer; 2016 Sep; 55(9):677-87. PubMed ID: 27121553
[TBL] [Abstract][Full Text] [Related]
5. Targetable molecular alterations in congenital glioblastoma.
Gilani A; Donson A; Davies KD; Whiteway SL; Lake J; DeSisto J; Hoffman L; Foreman NK; Kleinschmidt-DeMasters BK; Green AL
J Neurooncol; 2020 Jan; 146(2):247-252. PubMed ID: 31875306
[TBL] [Abstract][Full Text] [Related]
6. GOPC-ROS1 mosaicism in agminated Spitz naevi: report of two cases.
Goto K; Pissaloux D; Kauer F; Huriet V; Tirode F; de la Fouchardière A
Virchows Arch; 2021 Sep; 479(3):559-564. PubMed ID: 33733342
[TBL] [Abstract][Full Text] [Related]
7. Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report.
Wang J; Luo S; Li Y; Zheng H
Medicine (Baltimore); 2021 Jan; 100(3):e24377. PubMed ID: 33546077
[TBL] [Abstract][Full Text] [Related]
8. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
9. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
10. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
12. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
[TBL] [Abstract][Full Text] [Related]
13. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
14. Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme.
Lim SM; Choi J; Chang JH; Sohn J; Jacobson K; Policht F; Schulz J; Cho BC; Kim SH
PLoS One; 2015; 10(9):e0137678. PubMed ID: 26366867
[TBL] [Abstract][Full Text] [Related]
15. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma.
Gilani A; Siddiq Z; Kissell E; Kasson J; Kleinschmidt-DeMasters BK
Childs Nerv Syst; 2023 Jul; 39(7):1861-1868. PubMed ID: 36707425
[TBL] [Abstract][Full Text] [Related]
16. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
Karayan-Tapon L; Cortes U; Rivet P; Jermidi C; Vassal G; Wager M; Taillandier L
Eur J Cancer; 2014 Sep; 50(13):2364-6. PubMed ID: 24999209
[No Abstract] [Full Text] [Related]
17. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
20. Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
O'Neil SR; Weber GA; Deming DA; Burkard ME; Kenny PA; Richmond CS; Parsons BM
JCO Precis Oncol; 2023 Jul; 7():e2300174. PubMed ID: 37487149
[No Abstract] [Full Text] [Related]
[Next] [New Search]
